EPI 589

Drug Profile

EPI 589

Alternative Names: EPI-589

Latest Information Update: 19 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Edison Pharmaceuticals
  • Class Alkadienes; Benzoquinones; Cyclohexenes; Small molecules
  • Mechanism of Action Antioxidants; NAD(P)H dehydrogenase (quinone) modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 09 Jun 2015 Edison Pharmaceuticals plans a phase IIa trial for Parkinson's disease in USA (NCT02462603)
  • 08 Jun 2015 Edison Pharmaceuticals plans a phase IIa trial for Amyotrophic lateral sclerosis in USA (NCT02460679)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top